On March 17, the U.S. Food and Drug Administration (FDA) approved Cholbam (cholic acid) capsules, the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders. Read more.
FDA approves new treatment for rare bile acid synthesis disorders
Share